Patients divided over Alzheimer's drug: Is it a 'risk I'm willing to take' or just a 'magic pill'?

Medicare has proposed limiting coverage of Aduhelm, a costly new drug to treat Alzheimer’s disease, and prominent groups are pressing to make it more available. But among those facing the disease, the outlook is nuanced.

Related Keywords

New York ,United States ,Alabama ,United Kingdom ,North Carolina ,Albertville ,Washington ,Raleigh ,University Of Denver ,Colorado ,Colorado Springs ,Solebury ,Pennsylvania ,Canada ,Connecticut ,British ,Geri Taylor ,Rebecca Chopp ,Christine Thelker ,Phil Gutis ,Diana Blackwelder ,Jim Taylor ,Laurie Scherrer ,Jay Reinstein ,Dementia Alliance International ,Stage Advisory Group ,Dementia Action Alliance ,Alzheimer Association ,Centers For Medicare Medicaid Service ,Dementia Action Alliance Scherrer ,Medicaid Service January ,Early Stage Advisory Group ,Dementia Advocacy Canada ,New York City ,